Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Korosho to Select 5 Hub Med. Institutions for Early-stage Clinical Studies
July 4, 2011
- Tsuruha HD: Dispensing Fees Up 10.2% in FY2010
July 4, 2011
- EMA to Issue Conclusion on Bladder Cancer Risk from Actos in July
July 4, 2011
- AnGes MG Obtains Patent on HVJ-E for Cancer
July 4, 2011
- R&I Upgrades Kaken's Rating from “Stable”to “Positive”
July 4, 2011
- Takeda Applies for SGN-35 in Europe
July 4, 2011
- Current Users to Be Permitted to Rely on Telemarketing to Buy Reclassified Class 2 OTC Drugs
July 4, 2011
- R&I Keeps AA- Rating for Eisai
July 4, 2011
- Merck Serono Stops Global Approval Process for Cladribine
July 4, 2011
- 3 Groups Reconfirm Opposition to Deregulating Online Sale of OTC Drugs
July 4, 2011
- Mebiopharm to Be Listed on TOKYO AIM on July 15
July 4, 2011
- Largest No. of New Drugs Listed in FY2010 in the Past 15 Years: FPMAJ
July 4, 2011
- JPA Presents Its Opinions on OTC Drug Risk Reclassification to Korosho
July 4, 2011
- Combined Sales of 23 Japanese Drug Companies Reach ¥100 billion in China
July 4, 2011
- FDA Issues Warning on Bladder Cancer Risk Associated with Actos
June 27, 2011
- Pfizer to Conduct First-ever “Virtual Clinical Trial”
June 27, 2011
- Do Practice and Experience Maketh the Marketer?
June 27, 2011
- Korosho to Promptly Assess Bladder Cancer Risk due to Actos
June 27, 2011
- Dacogen Increases OS in AML Patients: Eisai
June 27, 2011
- Aratani Family Excluded from Teva-Controlled Taiyo
June 27, 2011
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…